임상시험
Finnish 10-year trial finds partial meniscectomy offers no benefit over sham surgery for degenerative meniscus tears
AI에 의해 보고됨 AI에 의해 생성된 이미지 사실 확인됨
A 10-year follow-up of the Finnish Degenerative Meniscal Lesion Study (FIDELITY) found that arthroscopic partial meniscectomy did not improve symptoms or knee function compared with placebo surgery, and patients assigned to the procedure tended to have worse long-term outcomes.
Intellia Therapeutics presented top-line data from its phase III HALO study in HAE during the Bank of America Global Healthcare Conference on May 12. The results showed substantial clinical benefits for patients with the condition.
AI에 의해 보고됨
Researchers from Australia have reported positive results from a Phase II clinical trial of a new carbohydrate-based drug for treating sepsis. The trial, involving 180 patients in China, demonstrated the drug's ability to reduce the condition's severity. This development offers hope for the first targeted therapy against a leading cause of global deaths.
A combination of enzalutamide and hormone therapy has reduced the risk of death by more than 40% in men with recurring prostate cancer, according to a major clinical trial. The study, involving over 1,000 patients worldwide, was led by researchers at Cedars-Sinai and presented at a medical congress in Berlin. Experts describe the findings as a game changer for treating aggressive cases.
AI에 의해 보고됨
The U.S. Food and Drug Administration has finalized a rule requiring drug sponsors to submit diversity action plans for clinical trials. This aims to ensure better representation of underrepresented groups in medical research. The rule takes effect in 2025.